Kolmar Korea Stock: The Other K-Beauty Arms Dealer (2026)

Every investor chasing the K-beauty boom eventually hits the same wall: the winning brands keep changing. One year it’s a sunscreen from a five-person startup; the next it’s a serum nobody had heard of. But whichever indie label wins, two Korean factories almost always made the product — Cosmax and Kolmar Korea. Cosmax is the one Western investors have started to name. Kolmar is the other arms dealer — and it is a stranger, more complicated animal than its twin.

🏭 What Does Kolmar Korea Actually Do?

Kolmar Korea is a contract manufacturer that designs and makes cosmetics, pharmaceuticals, packaging and health drinks for other companies’ brands — it is an ODM, not a brand you buy at the store. If you have used a Korean sunscreen, cushion foundation, or sheet mask in the last decade, there is a real chance a Kolmar factory formulated and filled it without its name ever appearing on the label.

The company sits at the centre of the K-beauty supply chain as a classic pick-and-shovel play. Thousands of indie Korean brands have no factories of their own; they hand a concept to Kolmar or Cosmax, which handles formulation, regulatory registration, and mass production. Unusually for an ODM, Kolmar names customers in its filings: Atomy, Carver Korea, CJ Olive Young, L&P Cosmetic and Goodai Global are listed as principal cosmetics clients, while LG H&H and Amorepacific are named on the packaging side (Source: DART FY2025 annual report, segment performance table).

Within cosmetics, the mix is heavily weighted to skincare rather than colour: basic skincare generated ₩1,106.0bn of segment sales in FY2025 against ₩368.7bn for colour cosmetics — about 75/25 (Source: DART FY2025 annual report). That mirrors Korea’s overall cosmetics export basket, which is likewise skincare-led. Geographically, though, Kolmar is more domestic than its “global ODM” billing implies: Korea accounted for ₩2,225.9bn of FY2025 revenue (82%), versus China ₩168.8bn (6%), the US ₩140.1bn (5%) and France ₩58.1bn (2%) (Source: DART FY2025 annual report, geographic segment note). Much of the “export” is Korean-invoiced product that leaves the country in a client’s box.

For a fuller map of the sector, see our pillar guide to K-beauty stocks for global investors, which lays out the brands, the devices, and the arms dealers side by side.

⚖️ Cosmax vs Kolmar: What’s the Real Difference?

The core difference is business mix: Cosmax earns 99.98% of its revenue from cosmetics, while Kolmar earns 53% — the rest coming from a consolidated pharma subsidiary, a loss-making packaging arm, and a small drinks business. They ride the same K-beauty tailwind, but they are not the same bet.

On pure cosmetics scale, Cosmax is meaningfully the bigger of the two: FY2025 revenue of ₩2,398.8bn, essentially all of it cosmetics, against Kolmar’s cosmetics segment of ₩1,440.9bn (Source: DART FY2025 annual reports for both companies). Kolmar’s consolidated revenue is larger — ₩2,722.4bn — precisely because it consolidates HK inno.N’s pharma sales on top of a smaller cosmetics base.

Sources: DART, Kolmar Korea FY2025 annual report and Cosmax Inc FY2025 annual report; company IR. Both P/Es use each company’s DART-reported EPS (Kolmar ₩5,299; Cosmax ₩10,847) over the Jul 28, 2026 KRX close.

The read for a foreign investor: if you want the cleanest possible exposure to K-beauty manufacturing volumes, Cosmax is the more direct instrument. If you want a diversified operator where a domestic drug franchise can offset a soft cosmetics quarter, Kolmar is the more defensive — and more complicated — one. Note also which segment is actually carrying Kolmar: pharma delivered a 11.2% operating margin in FY2025 versus 9.0% for cosmetics, while the packaging arm ran at a ₩3.0bn operating loss (Source: DART FY2025 segment note). The “K-beauty stock” is partly a pharma stock in disguise.

💊 Why Does HK inno.N Complicate the Story?

Because Kolmar Korea owns only 43.01% of HK inno.N but consolidates 100% of its revenue and profit — so a large slice of the reported earnings does not belong to Kolmar shareholders at all. This is the single most misunderstood feature of the stock.

Kolmar bought CJ Healthcare (now HK inno.N) in 2018 for ₩1.3tn, pivoting from generic-drug ODM work into branded pharma. HK inno.N’s flagship is K-CAB (tegoprazan), a home-grown gastric-reflux drug approved in Korea in July 2018 and on sale since January 2019. It is a genuinely valuable franchise — annual outpatient prescriptions reached ₩217.9bn in 2025, up from ₩110.7bn in 2021, and cumulative prescriptions since launch passed ₩1.0tn in April 2026, the first single Korean-developed new drug ever to do so (Source: UBIST data via Korean pharmaceutical press, 2026). HK inno.N itself crossed ₩1tn of annual revenue for the first time in FY2025, at ₩1,063.2bn (+18.5%), with net income of ₩75.7bn (Source: DART, Kolmar Korea FY2025 annual report).

But here is the accounting twist. Kolmar’s FY2025 consolidated net income was ₩168.2bn (+34.2% YoY). The portion attributable to Kolmar’s own shareholders — controlling-interest net income — was ₩125.1bn (Source: DART FY2025). The ₩43.1bn gap is almost exactly HK inno.N’s ₩75.7bn of FY2025 profit multiplied by the ~57% of it Kolmar does not own. Because Kolmar consolidates a subsidiary it only part-owns, the headline income overstates what an owner of 161890 actually earns.

📊 Valuation: What Are You Paying For the Growth?

At ₩98,900 (Jul 28, 2026 close), Kolmar trades at about 18.7× controlling-interest earnings with a market cap of ₩2.33tn (~$1.6B) — a growth multiple, not a value one. The stock is up ~59% year-to-date and sits 16% below its 52-week high of ₩117,800.

The bull case is momentum with substance. FY2025 operating income grew 23.6% to ₩239.6bn as operating margin widened to 8.8% from 7.9% (Source: DART FY2025 filing; see also Korea Herald) — real operating leverage, with profit growing twice as fast as the 11.0% revenue line. Foreign investors have backed it: net buyers of 529,786 shares over the trailing 20 sessions, including 212,709 in the last five, taking foreign ownership to 40.1% (Source: Naver Finance foreign-flow series, as of Jul 28, 2026). For how this fits the broader foreign bid, see our Foreign Flow Watch series.

The catch is that 18.7× earnings and a +59% YTD run already price in a lot of that good news. This is not a cheap stock hiding in plain sight; it is a quality operator you are paying up for. And one growth plank is still unconfirmed: after Korean media reported in March 2026 that Kolmar would become the country’s first “reshoring” company of the year with a ₩173.3bn skincare plant in Sejong, the company filed a clarification saying it had signed only a memorandum of understanding with Sejong City and that the investment period and amount remained under internal review. It has now deferred that confirmation three times — most recently on Jul 1, 2026, pushing the re-disclosure date to Sep 30, 2026 (Source: DART, “clarification of rumour or news report (undetermined),” Jul 1, 2026). Treat the Sejong plant as an option, not a plan.

🏛️ Governance & Shareholder Returns: Read This Before You Buy

Kolmar’s year-long family control fight is over — the founder withdrew his lawsuit in May 2026 — but the real overhang was never the litigation: it is that 88% of the vice chairman’s holding-company stake is pledged as collateral for margin loans. This is exactly the kind of ownership detail Western screens miss.

The control chain. At the top is Kolmar Holdings (KRX: 024720), the group’s listed holding company. Vice Chairman Yoon Sang-hyun personally holds 10,939,637 shares — 31.90% — and the family bloc of thirteen reporting parties holds 16,623,647 shares, or 48.47%, as of Jul 28, 2026. Founder Yoon Dong-han holds 5.59% and his daughter Yoon Yeo-won 7.60% (Source: DART large-holding report on Kolmar Holdings, filed Jul 28, 2026). Kolmar Holdings in turn is the top shareholder of Kolmar Korea (161890), which owns 43.01% of HK inno.N (195940).

One structural fact changed in 2026, and it went unreported in English. Kolmar Korea itself stopped being a holding company under Korea’s Fair Trade Act. Its holding ratio — the value of subsidiary shares as a proportion of total assets — fell below the 50% statutory threshold as of Dec 31, 2025; Kolmar filed for exemption on May 20, 2026 and the Fair Trade Commission confirmed on May 22, 2026 that it no longer qualifies (Source: DART, “material management matter relating to investment judgement,” May 22, 2026). In practice 161890 is now a cleaner operating company that happens to own four subsidiaries (HK inno.N 43.01%, Yonwoo 100%, MOD Materials 100%, Kolmar UX 100%), released from holding-company regulation — while the group’s chaebol-style layering still sits one level up, at Kolmar Holdings. To understand why structures like this depress valuations, see our explainer on the Korea Discount.

The family fight, and how it ended. The dispute began as a sibling disagreement over the group’s health-food affiliate, Kolmar B&H, and escalated when founder Yoon Dong-han sued his elder son in 2025 to reclaim 2.3 million Kolmar Holdings shares he had gifted him in 2019. In late May 2026 the founder withdrew the suit, ending roughly a year of open family conflict and consolidating Yoon Sang-hyun’s position (Source: Korean business press, May 27, 2026). For investors the read is two-sided: the succession risk premium should compress, but the pledge overhang is unaffected — and the vice chairman himself bought 49,321 shares on the market in July 2026, lifting his direct stake to 31.90%. Insiders buying is not the behaviour of a family under forced-sale pressure.

Scale brings scrutiny. In April 2026 the Kolmar group was designated a “disclosure-target business group” by Korea’s Fair Trade Commission, with group assets of ₩5.2428tn — the first cosmetics ODM group ever to cross the ₩5tn threshold (Source: KFTC designation announcement, Apr 29, 2026). Korean coverage framed this as a milestone and a burden, and both readings are right. Designation brings board-approval and public-disclosure requirements for internal transactions, plus exposure to Korea’s rules against improper benefit-shifting to controlling-family members. For minority shareholders the added transparency is arguably a net positive; for management it is new compliance cost and new legal risk on related-party dealings.

Shareholder returns are modest. Kolmar paid ₩864 per share for FY2025, up from ₩720, a ~0.9% yield — a cash payout ratio of 16.3% as reported by the company (Source: DART FY2025 dividend disclosure). That is conservative even for a growth-stage manufacturer, and roughly half what Cosmax pays out. There is no headline buyback-and-cancellation programme, and Kolmar is not a marquee name in Korea’s Value-Up reform the way some banks and holding companies have become. For income, this is not the stock; the thesis here is growth and operating leverage, not capital return.

🐻 The Bear Case: What Could Go Wrong?

The biggest risks to Kolmar Korea are thin ODM margins, dependence on a fast-churning indie-brand boom, a loss-making packaging arm, minority-interest leakage from the pharma leg, and a controlling family that has pledged most of its stake against loans. Any one of them can undo a stock priced for continued beats at ~18.7× earnings.

📚 Lingo Check

🎯 Why It Matters for K-Export Stars

Kolmar Korea is a textbook K-Export Star: an unglamorous factory that quietly exports the K-beauty boom to the world without ever putting its name on a bottle. It is the second of the two ODM “arms dealers,” and understanding how it differs from Cosmax — a 53/36 cosmetics-pharma split rather than a pure play, the minority-interest math, the pledge schedule, the quiet loss of holding-company status — is exactly the kind of primary-filing detail that gets lost when foreign coverage simply re-reports a Korean press release. Every number above came out of a DART document, not a wire story. If you are just getting started, our guide on how to buy Korean stocks as a foreign investor covers the mechanics of actually getting exposure to a KOSPI name like this one.

Disclaimer: This article is for informational and educational purposes only and is not investment advice, a recommendation, or a solicitation to buy or sell any security. Figures are drawn from public filings (DART), KRX market data, and company disclosures as of the dates noted, and may since have changed; prices and analyst targets go stale quickly. Always verify current data and consult a licensed financial professional before making any investment decision. The author holds no position in the securities mentioned at the time of writing.